Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Autors principals: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Elsevier
2019
|